* Newstin.co.uk is for sale! * After achieving our strategic milestone, we are offering for sale: Newstin.co.uk and all 14 related domains featuring 1 million unique visitors per month + continuously updated news database of 37 million articles in 12 world languages from 166,000 global and weighted sources + 2.1 billion metadata * To seize this unique chance, contact invest@newstin.com. * Newstin.co.uk is for sale! *

SkyePharma

SkyePharma bond renegotiation deal seen 'this week'

pharmiweb.co.uk
01-Sep-2008
        

LONDON, Sept 1 (Reuters) - Specialist drug delivery company SkyePharma Plc is set to announce a renegotiation of its convertible bonds this week, according to two analysts who cover the sector. Both analysts, who asked...

add comment
                   

SykePharma shares surge on hopes for bonds deal

pharmiweb.co.uk
29-Aug-2008
        

LONDON (Reuters) - Britain's SkyePharma Plc, a specialist in drug delivery technology, said on Thursday it was close to a deal on renegotiating its convertible bonds, sending the company's shares 20 percent higher. The...

add comment
                   

SkyePharma: Interim Results Announcement for the Six Months Ended 30 June 2008

pharmiweb.co.uk
28-Aug-2008 5 related
        

shortly. Jeremy Scudamore, Non-Executive Chairman, said: “In the last six months SkyePharma has made significant progress on several fronts. Positive Flutiform™ data has now been received from seven Phase III clinical...

add comment
                   

SkyePharma first-half loss narrows - Quick Facts

pharmiweb.co.uk
28-Aug-2008
        

8/28/2008 3:42 AM ET (RTTNews) - SkyePharma PLC (SKP.L: News ,SKYE: News ) reported first-half loss of GBP 6.8 million or 0.8 pence per share, compared to loss of GBP 19.6 million or 2.5 pence per share last year. The...

add comment
                   

Mylan Launches Generic Hypertension Drug

pharmiweb.co.uk
04-Aug-2008 5 related
        

Mylan Pharmaceuticals has received final FDA approval for generic versions of Sciele Pharma’s anti-hypertensive Sular extended release (ER) in 20-, 30- and 40-mg strengths. Mylan’s nisoldipine ER is the first generic version of...

add comment

Sciele Pharma, Inc. Reports Results for the Second Quarter of 2008

finanznachrichten.de
30-Jul-2008 886 related
        

Sciele Pharma, Inc. (NASDAQ:SCRX): Second quarter 2008 financial results include: Pro forma diluted net income per share, a non-GAAP measure, was $0.46, excluding $0.11 in charges related to Sular returns and validations,...

add comment
genengnews.com: Genetic Engineering genengnews.com

Sciele Pharma, Inc. Reports Results for the Second Quarter of 2008

genengnews.com
30-Jul-2008 434 related
        

News source: Business Wire Sciele Pharma, Inc. : Second quarter 2008 financial results include: -- We also have diversified our product portfolio - with approximately 20% of the Company's revenues in the first half of 2008...

add comment

SkyePharma stock rises again thanks to Flutiform trials success

pharmiweb.co.uk
24-Jul-2008 4 related
        

SkyePharma has seen an upturn in its shattered share price after the company said that two more late-stage studies for its flagship asthma combination drug Flutiform have been successfully completed. The studies were undertaken...

add comment

SkyePharma Announces Positive Results for Two European Studies for Flutiform

pharmiweb.co.uk
23-Jul-2008 7 related
        

SkyePharma Posted on:23 Jul 08 LONDON, UK 22 July 2008 - SkyePharma PLC (LSE: SKP) today announces that its development and marketing partner Mundipharma has successfully completed two Phase III clinical studies for the...

add comment

Big trade in Rift Oil after new gas find

timesonline.co.uk
21-Jul-2008
        

Rift Oil, which is drilling for gas in Papua New Guinea, was one of the most heavily traded shares on the London market, with 21 million changing hands after the company said that it had been successful beyond its “most...

add comment